Estimating potential silent transfer using baseline viral load measures among people presenting as new to HIV care in Lusaka, Zambia: a cross-sectional study

Objectives To estimate potential silent transfer using baseline viral load measures among individuals presenting as new to HIV care in routine HIV clinical settings in Lusaka, Zambia. Design Cross-sectional study. Setting Two large, urban government-operated health facilities supported by the Centre for Infectious Disease Research in Zambia. Participants A total of 248 participants with an incident positive HIV rapid test. Outcome measures The primary outcome measure was HIV viral suppression at baseline (i.e., potential silent transfer), defined as having a viral load ≤1000 RNA copies(c)/mL at the time of initiating HIV care. We also examined viral suppression at ≤60 c/mL. Methods We surveyed and measured baseline HIV viral load as part of the national recent infection testing algorithm among people living with HIV (PLWH) presenting as new to care. Using mixed effects Poisson regression, we identified characteristics among PLWH associated with potential silent transfer. Results Among the 248 PLWH included, 63% were women with median age of 30, and 66 (27% (66/248)) had viral suppression at ≤1000 c/mL and 53 (21% (53/248)) at ≤60 c/mL thresholds, respectively. Participants aged 40+ years had a significantly higher adjusted prevalence of potential silent transfer (adjusted prevalence ratio (aPR): 2.10; 95% CI: 2.08, 2.13) compared with participants aged 18–24 years. Participants reporting no formal education had a significantly higher adjusted prevalence of potential silent transfer (aPR: 1.63; 95% CI: 1.52, 1.75) compared with those completing primary education. Among 57 potential silent transfers who completed a survey, 44 (77%) indicated having tested positive previously at ≥1 of 38 clinics in Zambia. Conclusions The high proportion of PLWH with potential silent transfer points to clinic shopping and/or co-enrolment at multiple care sites simultaneously, suggesting an opportunity to improve care continuity at the time of HIV care entry.

[1]  M. Nolan,et al.  Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: an observational study nested within a randomized controlled trial , 2021, BMC Infectious Diseases.

[2]  N. Ford,et al.  The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals , 2021, PLoS medicine.

[3]  P. Ehrenkranz,et al.  Patterns and Predictors of Incident Return to HIV Care Among Traced, Disengaged Patients in Zambia: Analysis of a Prospective Cohort , 2020, Journal of acquired immune deficiency syndromes.

[4]  E. Geng,et al.  Understanding patient transfers across multiple clinics in Zambia among HIV infected adults , 2020, PloS one.

[5]  Miquel Duran-Frigola,et al.  Patient‐reported reasons for declining same‐day antiretroviral therapy initiation in routine HIV care settings in Lusaka, Zambia: results from a mixed‐effects regression analysis , 2020, Journal of the International AIDS Society.

[6]  A. Kim,et al.  Tracking with recency assays to control the epidemic , 2019, AIDS.

[7]  D. Glidden,et al.  Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment , 2019, Journal of acquired immune deficiency syndromes.

[8]  E. Geng,et al.  ‘They care rudely!’: resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia , 2018, BMJ Global Health.

[9]  N. Padian,et al.  Understanding preferences for HIV care and treatment in Zambia: Evidence from a discrete choice experiment among patients who have been lost to follow-up , 2018, PLoS medicine.

[10]  W. MacLeod,et al.  Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa , 2018, PLoS medicine.

[11]  N. Ford,et al.  Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa , 2018, PloS one.

[12]  Carolyn Bolton Moore,et al.  Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey , 2018, PLoS medicine.

[13]  W. El-Sadr,et al.  Selecting a viral load threshold for routine monitoring in resource‐limited settings: optimizing individual health and population impact , 2017, Journal of the International AIDS Society.

[14]  E. Geng,et al.  Movement between facilities for HIV care among a mobile population in Kenya: transfer, loss to follow-up, and reengagement , 2016, AIDS care.

[15]  C. Yiannoutsos,et al.  Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  N. Ford,et al.  Self‐transfer and mortality amongst adults lost to follow‐up in ART programmes in low‐ and middle‐income countries: systematic review and meta‐analysis , 2015, Tropical medicine & international health : TM & IH.

[17]  J. Eaton,et al.  A Side Door Into Care Cascade for HIV-Infected Patients? , 2013, Journal of acquired immune deficiency syndromes.

[18]  M. Newell,et al.  Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa , 2013, Tropical medicine & international health : TM & IH.

[19]  C. Yiannoutsos,et al.  Retention in Care and Connection to Care among HIV-Infected Patients on Antiretroviral Therapy in Africa: Estimation via a Sampling-Based Approach , 2011, PloS one.

[20]  S. Lawn,et al.  Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa , 2011, Journal of acquired immune deficiency syndromes.

[21]  N. Ford,et al.  Treatment Interruption in a Primary Care Antiretroviral Therapy Program in South Africa: Cohort Analysis of Trends and Risk Factors , 2010, Journal of acquired immune deficiency syndromes.

[22]  F. Pereyra,et al.  Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. , 2009, The Journal of infectious diseases.

[23]  R. Siliciano,et al.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.